DLBCL IPI Prognosis Calculator

About the DLBCL IPI Prognosis Calculator

The DLBCL IPI (International Prognostic Index) Prognosis Calculator estimates outcomes for patients with diffuse large B-cell lymphoma — the most common aggressive non-Hodgkin lymphoma, accounting for approximately 30–40% of all NHL cases. The IPI, developed in 1993 from a study of 2,031 patients, remains the most widely used prognostic tool in aggressive lymphoma.

The index evaluates five independent adverse prognostic factors: age over 60, advanced stage (III/IV), elevated LDH, poor performance status (ECOG ≥2), and more than one extranodal site. Each factor adds one point, generating a score from 0–5 that classifies patients into four risk groups with distinct expected outcomes in terms of complete response rates and overall survival.

This worksheet compares the original IPI and the revised IPI so the published prognostic context stays visible alongside cell-of-origin notes. It also incorporates cell-of-origin subtyping (GCB vs. non-GCB/ABC), which has emerged as an important prognostic and treatment-guiding biomarker.

When This Page Helps

The IPI helps organize published prognostic context and can support treatment discussions, follow-up planning, and clinical trial consideration. It should be interpreted alongside pathology, molecular findings, and the overall treatment plan.

How to Use the Inputs

1. Enter the patient's age.
2. Select the Ann Arbor stage (I through IV).
3. Enter the serum LDH and your laboratory's upper limit of normal.
4. Select the ECOG performance status (0–4).
5. Indicate the number of extranodal disease sites.
6. Select the cell-of-origin subtype if known.
7. Review the IPI score, risk group, and expected outcomes.

Example Calculation

Tips & Best Practices

• The R-IPI (revised for rituximab era) better predicts outcomes for patients receiving R-CHOP — prefer R-IPI for modern treatment.
• Cell-of-origin subtyping (GCB vs. ABC/non-GCB) adds prognostic information beyond IPI. ABC subtype has worse prognosis but may benefit from targeted agents like ibrutinib or lenalidomide.
• Double-hit lymphomas (MYC + BCL2/BCL6 rearrangements) have poor prognosis regardless of IPI — FISH testing should be performed on all DLBCL.
• Young patients (<60) with high IPI may benefit from dose-intensified regimens (DA-EPOCH-R) or clinical trial enrollment.
• IPI was developed in the pre-rituximab era — absolute survival figures have improved significantly with R-CHOP.
• PET-CT after 2 cycles (interim PET) provides additional prognostic information beyond baseline IPI.

The Evolution of Prognostic Models in DLBCL

The IPI was originally developed in 1993 from 2,031 patients treated with anthracycline-based chemotherapy (CHOP) before the rituximab era. With the addition of rituximab (R-CHOP) as standard of care in the early 2000s, outcomes improved substantially, and the R-IPI was developed to better discriminate risk groups in the modern treatment era. Some newer models (NCCN-IPI) use more refined age and LDH thresholds for improved prognostication.

Molecular Subtypes and Targeted Therapy

Beyond the IPI, molecular characteristics increasingly guide treatment decisions. High-grade B-cell lymphoma with MYC and BCL2 rearrangements (double-hit) requires intensified therapy. ABC/non-GCB subtype may benefit from BTK inhibitors (ibrutinib) or immunomodulatory agents (lenalidomide) added to R-CHOP. Ongoing clinical trials are investigating subtype-directed therapy to improve outcomes in high-risk groups.

Treatment Advances Beyond R-CHOP

Recent advances include: polatuzumab vedotin + R-CHP (POLARIX trial — improved PFS vs. R-CHOP), CAR-T cell therapy for relapsed/refractory disease (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel), bispecific antibodies (glofitamab, epcoritamab, mosunetuzumab), and antibody-drug conjugates (loncastuximab tesirine). These have transformed the treatment landscape for patients who relapse after initial therapy.

Frequently Asked Questions

• What is DLBCL?

  Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of aggressive (fast-growing) non-Hodgkin lymphoma, accounting for 30–40% of all NHL cases. It arises from mature B lymphocytes and typically presents as rapidly enlarging lymph nodes, often with systemic symptoms (fever, night sweats, weight loss). Despite its aggressive nature, DLBCL is curable in 60–70% of cases with standard immunochemotherapy.

• What is the standard treatment for DLBCL?

  R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone) given every 21 days for 6 cycles is the standard first-line treatment. For limited-stage disease (stages I–II), abbreviated chemotherapy (3–4 cycles) plus involved-field radiation may be used. Polatuzumab vedotin was recently added in first-line (Pola-R-CHP) based on the POLARIX trial.

• What does the IPI predict?

  The IPI predicts the likelihood of complete response to treatment and overall survival at 5 years. Low-risk (0–1 points) patients have 73% 5-year OS and 87% CR rate. High-risk (4–5 points) patients have 26% 5-year OS and 44% CR rate. These figures are from the pre-rituximab era; modern outcomes with R-CHOP are significantly better across all groups.

• What is the difference between IPI and R-IPI?

  The revised IPI (R-IPI) was recalibrated for the rituximab era. It uses the same 5 factors but groups patients into 3 categories: Very Good (score 0, 4-year OS 94%), Good (score 1–2, 4-year OS 79%), and Poor (score 3–5, 4-year OS 55%). R-IPI better discriminates outcomes for patients receiving R-CHOP.

• What is cell of origin and why does it matter?

  DLBCL can be classified by cell of origin into GCB (germinal center B-cell, ~50%) and ABC/non-GCB (activated B-cell, ~35%). GCB subtype has better prognosis with standard R-CHOP. ABC subtype is associated with poorer outcomes and may benefit from targeted therapies (ibrutinib, lenalidomide). Determination is made by immunohistochemistry (Hans algorithm) or gene expression profiling.

• What are double-hit lymphomas?

  Double-hit lymphomas (DHL) harbor concurrent rearrangements of MYC and BCL2 (and/or BCL6), identified by FISH testing. They represent 5–10% of DLBCL and have significantly worse prognosis (5-year OS 30–40%) regardless of IPI score. Treatment typically involves intensified regimens like DA-EPOCH-R rather than standard R-CHOP.